Table 2. Effect of TXA on primary and secondary endpoints.

	Baseline Mean (SD)	Follow-Up Mean (SD)	Baseline/Follow-Up Mean Difference (95% CI)	DID: TXA / Placebo groups Mean DID ( 95%CI) p Value
ETP(nM*min)
TXA (N=87)	1537 (375.9)	1494 (369.1)	43.2 [-16.6; 103.1]	36.63 [-42.9; 120.0] p raw = 0.350 * 29.81 [-47.8; 107.4] p adj = 0.453 **
Placebo (N=94)	1491 (378.7)	1487 (390.5)	4.6 [-51.4; 60.6]
ADPtest(AU*min)
TXA (N=89)	1043.0 (343.6)	964.7 (312.4)	78.0 [15.4; 140.6]	13.2 ( -65.8; 92.2) p raw= 0.7 * -0.9 ( -72.7; 70.9) p adj = 1.0 **
Placebo (N=91)	961.6 (339.6)	896.8 (356.8)	64.8 (15.8; 113.7)
TRAPtest(AU*min)
TXA (N=89)	1199 (362.3)	1093 (300.3)	106.2 (38.5; 174.0)	20.9 ( -65.3; 107.1) p raw= 0.6 * 1.5 ( -72.8; 75.7) p adj = 1.0 **
Placebo (N=91)	1156 (347.9)	1070 (336.8)	85.3 (31.2; 139.4)
Factor V (%)
TXA (N=88)	103.4 (27.7)	103.4 (25.7)	0.1 (-4.6; 4.8)	-4.2 ( -10.0; 1.7) p raw= 0.2 * -4.9 ( -10.4; 0.7) p adj = 0.1 **
Placebo (N=94)	100.2 (28.5)	95.9 (29.2)	4.3 (0.7; 7.8)
Factor VIII (%)
TXA (N=88)	221.9 (102.4)	216.1 (87.4)	5.9 (-9.5; 21.2)	5.9 ( -13.9; 25.6) p raw= 0.6 * -0.9 ( -18.7; 17.6) p adj = 1.0 **
Placebo (N=94)	195.2 (87.0)	195.2 (87.4)	0.0 (-12.7; 12.7)
Factor vW (%)
TXA (N=88)	219.4 (89.8)	222.2 (89.1)	-2.8 (-15.2; 9.7)	-0.1 ( -16.9; 16.7) p raw= 1.0 * 1.3 ( -15.0; 17.5) p adj = 0.9 **
Placebo (N=94)	212.6 (92.6)	215.3 (92.0)	-2.7 (-14.1; 8.8)
Fibrinogen (g/L)
TXA (N=87)	3.64 (1.09)	3.59 (1.07)	0.05 (-0.1; 0.2)	-0.08 (-0.29; 0.12) P raw= 0.4 * -0.09 (-0.28; 0.1) p adj = 0.4 **
Placebo (N=93)	3.49 (1.2)	3.36 (1.1)	0.13 (-0.01; 0.27)
D-Dimer (mg/L)
TXA (N=88)	7.4 (9.3)	7.8 (10.2)	-0.4 (-1.1; 0.3)	0.9 ( -1.3; 3.0) p raw= 0.4 * 1.5 ( -0.2; 3.1) p adj = 0.1 **
Placebo (N=94)	9.6 (24.6)	10.8 (17.7)	-1.3 (-3.4; 0.8)

Population: Patients were difference could be calculated (N); DID: Difference in Differences

Analysis: * raw (simple 95% CI of DID); ** adjusted for baseline and time between samples